

Date:11.10.2023

To Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001

Dear Sir/Madam,

BSE Scrip: PHARMAID | Code: 524572 ISIN: INE117D01018|

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Pendency of any litigation(s) or dispute(s)

With reference to the captioned subject and pursuant to Regulation 30 read with Para B of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (SEBI LODR), details with respect to the pending litigations, as required under Regulation 30 of the SEBI LODR read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, are enclosed in the **Annexure I.**

This is for your information and records.

Yours sincerely,

For Pharmaids Pharmaceuticals Limited

KAUSHI Digitally signed by KAUSHIK KUMAR KUMAR KUMAR 2023.10.11 16:22:26 +05'30'

Kaushik Kumar (Company Secretary & Compliance Officer)



Annexure I

Disclosure as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, and SEBI Circular SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023:

Sr.No	Details of Events that need to be provided.	Information of such events(s)
a	Brief details of litigation	
i	Name(s) of the opposing party	United Biotech Private Limited
ii	Court / tribunal / agency where litigation is filed	IP Division of Madras High Court
iii	Brief details of dispute/ litigation	A Petition was filed by United Biotech Private Limited against the Company before Hon'ble Madras High Court requesting that the Company should forego the trademark related to one of its products. The Company is currently evaluating the petition filed by United Biotech Private Limited and has sought time from the court to file its reply.
b	Expected financial implications, if any, due to compensation, penalty etc.	The expected financials implication cannot be determined at this stage as the matter is currently pending before the authority.
с	Quantum of claims if any	NA